Preclinical study demonstrates that Piezo1 directs TH9 cell differentiation in CD4+ T cells, indicating novel metabolic targets for cancer immunotherapy.
Interleukin (IL)-9-producing CD4 + T cells (T H 9) are essential for mediating antitumor immunity, but the mechanisms of T H 9 cell differentiation remain unclear. Here, we found that the mechanical force receptor Piezo1 is critical for regulating T H 9 cell differentiation. Piezo1 deficiency in CD4 + T cells intrinsically inhibited T H 9 cell differentiation, whereas ectopic Piezo1 expression promoted this process. Notably, Piezo1 deficiency inhibited T H 9 cell differentiation and contributed to tumor development. Mechanistically, Piezo1 deficiency inhibits T H 9 cell differentiation mainly through the SIRT3-succinate dehydrogenase A (SDHA)-oxidative phosphorylation (OXPHOS) pathway. SIRT3 deficiency or blockade of SDHA-OXPHOS signaling activity reversed the T H 9 cell differentiation induced by Piezo1 deficiency. Moreover, HIF1α signaling is responsible for the T H 9 cell differentiation induced by Piezo1 deficiency. Thus, our findings identify a redox metabolism signaling mechanism regulated by the mechanical force receptor Piezo1 that limits the mitochondrial SIRT3-SDHA-dependent OXPHOS pathway and triggers HIF1α-IL-9 to reprogram T H 9 cell differentiation, with implications for future immunotherapy approaches.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: